Cannabinoids and Traumatic Brain Injury: A Randomized, Placebo Controlled Trial

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2023
This is a double-blind, placebo-controlled, parallel group study designed to assess the tolerability and efficacy of fsCBD and bsCBD, compared to a placebo control, to improve cognition and traumatic brain injury-related symptoms. If eligible for the study, subjects will be randomized to receive one of the conditions for 12 weeks.
Epistemonikos ID: 62373f5e3d5aaa4613af14e0c813a4269ba5686a
First added on: May 14, 2024